64
Table 2 (continued)
Compound
Pharmaceutical
activity
Optimal deep eutectic
solvent composition(s)
Therapeutic
deep
eutectic
solvents
References
Naproxen
Antiinflammatory
CC:U 1:2; CC:GL 1:2
Lu et al. (2016)
Naproxen
Antiinflammatory
CC:EG 1:2; CC:U 1:2;
CC:MOA 1:1
Mokhtarpour
et al. (2019a)
Naringin
dihydrochalcone
Antioxidant
CA:G:W 1:1:12;
CC:CA:W 1:1:11;
CC:G:W 1:1:11
Tang et al.
(2016)
Nobiletin
Glucoselowering agent
C:GE 1:2
Hattori et al.
(2019)
Paclitaxel
Anticancer
CC:G
Choi et al.
(2011)
Paracetamol
Antalgic
CC:drug
✓
Abbott et al.
(2017)
Paracetamol
Antalgic
Drug:phenol
✓
Potticary et al.
(2019)
Paracetamol
Antalgic
CC:drug
✓
Abranches
et al. (2019)
Phenylacetic acid
Model drug
CC:drug and
menthol:drug
✓
Aroso et al.
(2016) and
Duarte et al.
(2017)
Phenylacetic acid
Model drug
Various HBA
✓
Wolbert et al.
(2019)
Phloretin
Antioxidant
CC:S:W 1:1:10;
CC:CA:W 1:1:11
Tang et al.
(2016)
Phlorizin
Antioxidant
CA:G:W 1:1:12;
CC:CA:W 1:1:11;
CC:G:W 1:1:11
Tang et al.
(2016)
Piroxicam
Antiinflammatory
CC:GA 1:2; CC:GA:OA
1:1.7:0.3
Li and Lee
(2016)
Posaconazole
Antifungal
CC:GA 1:2; CC:GA:OA
1:1.7:0.3
Li and Lee,
(2016)
Prilocaine
Local anesthetic Lidocaine
✓
Wojnarowska
et al. (2018)
Quercetin
Various (natural
flavonoid)
X:CC:W 1:2:3
Dai et al.
(2013, 2015)
Ranitidine
Antihistaminic Drug with GL, U, or
aspirin
✓
Abbott et al.
(2017)
Resveratrol
Antioxidant
PD:CC:W 1:1:1
Shamseddin
et al. (2017)
Rutin
Various (natural
flavonoid)
G:CC:W 2:5:5
Dai et al.
(2013)
(continued)
C.-H. Nguyen et al.